1. Introduction
===============

Schiff base ligands containing various donor atoms (like N, O, S, *etc*.) show broad biological activities and are of special interest due to variety of ways in which they can bond to metal ions. It is known that the existence of metal ions bonded to biologically active compounds may enhance their activities \[[@B1-molecules-17-05952]\]. Schiff base metal complexes show great diversity in their varied biological activities as anticonvulsant \[[@B2-molecules-17-05952]\], antifungal \[[@B3-molecules-17-05952],[@B4-molecules-17-05952],[@B5-molecules-17-05952],[@B6-molecules-17-05952],[@B7-molecules-17-05952]\], anti-HIV \[[@B8-molecules-17-05952]\], antiviral and anticancer \[[@B9-molecules-17-05952]\] antimicrobial \[[@B10-molecules-17-05952],[@B11-molecules-17-05952],[@B12-molecules-17-05952],[@B13-molecules-17-05952],[@B14-molecules-17-05952],[@B15-molecules-17-05952]\] and antibacterial \[[@B16-molecules-17-05952]\] agents.

Nosocomial infections caused by multidrug resistant bacteria are an increasing medical problem worldwide, particularly among immunocompromised patients and those hospitalized in intensive care units. Both Gram positive and Gram negative bacteria have developed high level resistance to multiple classes of antibacterial agents. These include methicillin resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Escherichia coli* and vancomycin resistant enterococci (VRE) \[[@B17-molecules-17-05952]\]. Few available drugs such as linezolid and some newer glycopeptides, and tigecycline are active against MRSA and VRE, but their success rates are variable \[[@B18-molecules-17-05952]\]. As such, there is a need to explore other sources of effective antibacterial compounds to augment the limited choice of drugs for therapeutic treatment.

In this study, transition metal complexes of some newly synthesized *N,N′,N′*′-donor Schiff base ligands obtained from the reaction of 4-(2-aminoethyl)morpholine, 4-(2-aminoethyl)piperazine or *N,N*-dimethylethylenediamine with 2-acetylpyridine in the presence of Cl^−^, Br^−^, and SCN^−^ ions were examined for potential antimicrobial activities. Most of the synthesized compounds present a morpholine derivative which has been used as a building block for preparation of the antibiotic linezolid \[[@B19-molecules-17-05952],[@B20-molecules-17-05952]\]. The morpholine ring is important for antimicrobial activity as proved by quantitative structure activity relationship (QSAR) \[[@B21-molecules-17-05952]\]. The objective of the study was to determine the anti-bacterial activities for the transition metals complexes against methicillin-resistant *Staphylococcus aureus* (MRSA), *Acinetobacter baumanni* (*A. baumanni*), *Klebsiella Pneumonie* (*K. pneumonie*) and *Pseudomonas aeruginosa* (*P. aeruginosa*) by using the disc diffusion and micro broth dilution assays.

2. Results and Discussion
=========================

The reaction of 2-acetylpyridine with 4-(2-aminoethyl)morpholine, 4-(2-aminoethyl)piperazine or *N,N*-dimethylethylenediamine resulted in the formation of corresponding Schiff base ligands; 2-morpholino-*N*-(1-(pyridin-2-yl)ethylidene)ethanamine (**1**), 2-(piperazin-1-yl)-*N*-(1-(pyridin-2-yl)-ethylidene)ethanamine (**2**), *N1,N1*-dimethyl-*N2*-(1-(pyridin-2-yl)ethylidene)ethane-1,2-diamine (**3**). The prepared Schiff bases further reacted cadmium(II), copper(II), nickel(II) and zinc(II) ions in the presence of Cl^−^, Br^−^, SCN^−^ ions giving rise to different coordination complexes ([Scheme 1](#molecules-17-05952-f004){ref-type="fig"}). The compounds exhibited NMR, IR and UV-Visible spectra consistent with the proposed structures which allowed the synthesized complexes to be recognized as aqua{dithiocyanato-(2-morpholino-*N*-\[1-(2-pyridylethylidene\]ethanamine *N,N′,N′*′}cadmium(II) (**4**), aqua{dichloridopiperazin-4-ium1-(2-pyridyl) ethylidene\]ethanamine *N,N′,N′*′}cadmium (**5**), chlorido(2-{1-\[(2-morpholinoethyl)imino\]ethyl}-phenolato *N,N′,N′*′)copper(II) (**6**), dibromido{2-morpholino-*N*-\[1-(2-pyridyl)ethylidene)ethanamine *N,N′,N′*′}cadmium (**7**), dibromido{2- *N,N′,N′*′}bis(thiocyanato) nickel(II) (**10**), respectively. In this context, it would be worthy morpholino-*N*-\[1-(2-pyridyl)ethylidene\] ethanamine *N,N′,N′*′} zinc (**8**), *N,N*-dimethyl-*N'*-\[1-(2-pyridyl)ethylidene\]ethane-1,2-diamine-^3^*N,N′,N′*′}bis(thiocyanate) zinc(II) (**9**), and aqua{2-morpholino-*N*-\[1-(2-pyridyl)ethylidene\]ethanamine to compare the structures of some earlier prepared complexes with the present ones. There are two reported complexes of nickel(II) perchlorate with the similar donor-Schiff base ligand \[[@B22-molecules-17-05952]\].

![Reaction pathway for the coordinated complexes.](molecules-17-05952-g004){#molecules-17-05952-f004}

2.1. Infrared Spectra
---------------------

The IR spectra of the compounds were recorded in the 4000--400 cm^−1^ range. The characteristic IR stretching frequencies along with their proposed assignments are summarized in the Experimental section. There are similarities in the IR spectra of the ligands and their corresponding metal complexes to each other, except for some slight variations in the shifts and intensities caused by different metal(II) ions. However, there were some significant differences between the metal(II) halides complexes and those of the thiocyanate complexes, as expected. The IR spectra of all the compounds possess very strong characteristic absorption bands in the 1,585--1,656 cm^−1^ region which are attributed to the C=N stretching vibration of the Schiff base functional group \[[@B11-molecules-17-05952],[@B23-molecules-17-05952],[@B24-molecules-17-05952]\]. The hydrated complexes (**4**, **5** and **10**) exhibited an IR band at approximately 650--700 cm^−1^ range due to ν(H~2~O), suggesting the coordination of water molecules \[[@B25-molecules-17-05952],[@B26-molecules-17-05952]\]. The characteristic sharp and distinct absorption bands for N=C=S appear in the 2,030--2,120 cm^−1^ region for compounds **4**, **9** and **10** \[[@B27-molecules-17-05952],[@B28-molecules-17-05952]\]. All complexes showed M-N bands at a lower wavelength in the range of 454--556 cm^−1^ \[[@B29-molecules-17-05952],[@B30-molecules-17-05952],[@B31-molecules-17-05952],[@B32-molecules-17-05952]\].

2.2. Electronic Spectra
-----------------------

The electronic spectra for all the compounds were obtained in DMSO solutions and showed absorption bands in three distinct regions. The first region ranging from 200 to approximately 229 nm, is characteristic for the electronic inter-ligand π→π\* transitions \[[@B33-molecules-17-05952]\], while the second characteristic wavelength in the region of 280 nm to approximately 350 nm is the second inter ligand n→π transition \[[@B34-molecules-17-05952]\]. The third distinct region ranging from 407 nm to approximately 500 nm is the characteristic for the ligand to metal charge transfer (LMCT) from the nitrogen atom to the transition metal centre \[[@B35-molecules-17-05952]\]. For the nickel(II) and copper(II) ions, bands were observed between 600 and 750 nm which can be attributed to d--d\* transitions of the metal ions respectively \[[@B36-molecules-17-05952]\].

2.3. ^1^H- and ^13^C-NMR-NMR Spectra
------------------------------------

The signals for the aromatic ring protons appear in the region of 7.80--8.80 \[[@B37-molecules-17-05952]\]. While the other singlet peaks appeared in the region of 1.80--2.65 ppm which were attributed to CH~3~ indicating the methyl on the carbonyl group \[[@B37-molecules-17-05952]\]. Also in the piperazine compound **5** additional signals was observed at 2.30 ppm which was assigned to (NH--). In the ^13^C-NMR spectra of the metal complexes, the signals in the range from 160.00--170.00 ppm were assigned to azomethine carbon atoms (C=N) \[[@B32-molecules-17-05952]\]. Aromatic ring carbon atoms were determined in the range of 120.00--150.00 ppm \[[@B37-molecules-17-05952]\]. Additional signals were observed at 21.98 ppm and 22.75 ppm, which were assigned to the carbon atom of (N*C*S) for compounds **4** and **9**, respectively.

2.4. X-Ray Crystal and Molecular Structure
------------------------------------------

Compound **8** was obtained upon the reaction of 2-morpholino-*N*-\[1-(2-pyridyl)ethylidene\]-ethanamine with Zn(II) ion in the presence of potassium bromide. Similar to the structure of the analogous ZnCl~2~ complex \[[@B38-molecules-17-05952]\], the metal center is five-coordinated by the *N,N′,N′′-*tridentate Schiff base ligand and two halogen atoms ([Figure 1](#molecules-17-05952-f001){ref-type="fig"}).

![The molecular X-ray structure of **8** and **9** showing the atom labeling scheme (50% probability ellipsoids). Hydrogen atoms are drawn as spheres of arbitrary radius.](molecules-17-05952-g001){#molecules-17-05952-f001}

The geometry of the complexes can be determined by using the index τ = (β-α)/60, where β is the largest angle and α is the second one around the metal center. For an ideal square-pyramid τ is 0, while it is 1 in a perfect trigonal-bipyramid \[[@B39-molecules-17-05952]\]. The τ value in the present structure is calculated to be 0.30, indicative of a distorted square-pyramidal geometry. The Zn-Br and Zn-*N* bond lengths in the complex are in agreement with the values reported in the literature \[[@B40-molecules-17-05952],[@B41-molecules-17-05952]\]. The Zn(II) ion in the compound, is five-coordinated by the *N,N′,N′′-*tridentate Schiff base ligand and two Br atoms in a distorted square-pyramidal geometry. The three Zn-N bond lengths as apparent from ([Table 1](#molecules-17-05952-t001){ref-type="table"}) are given as Zn(1)-*N*(1) 2.243(3) Å, Zn(1)-N(2) 2.076(2) Å, Zn(1)-N(3) 2.331(2) Å, and two Zn-Br bond lengths are Zn(1)-Br(1) 2.4036(4) (18) Å, Zn(1)-Br(2) 2.4172(4) Å. In the crystal, intermolecular C\-\--H\...Br hydrogen bonds link the adjacent molecules into infinite chains along the crystallographic axis. An intramolecular C\-\--H\...Br interaction is also observed. [Table 2](#molecules-17-05952-t002){ref-type="table"} summarizes the crystal data for compounds **8** and **9** zinc(II) complexes.
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###### 

Selected bond lengths \[Ǻ\] and Selected bond angles \[°\] for compounds **8** and **9**.

  8     9                                                         
  ----- ----- ----------- ------------- ------ ------------ ----- ------------
  Zn1   Br1   2.4036(4)   Zn1           N1     2.1752(18)         
  Zn1   Br2   2.4172(4)   Zn1           N2     2.0752(18)         
  Zn1   N1    2.243(3)    Zn1           N3     2.217(2)           
  Zn1   N2    2.076(2)    Zn1           N4     1.9681(18)         
  Zn1   N3    2.331(2)    Zn1           N5     1.9698(19)         
  Br1   Zn1   Br2         116.905(15)   N1     Zn1          N3    154.18(7)
  N1    Zn1   Br1         92.48(6)      N2     Zn1          N1    75.30(7)
  N1    Zn1   Br2         95.00(6)      N2     Zn1          N3    79.64(8)
  N1    Zn1   N3          151.50(8)     N4     Zn1          N1    97.48(7)
  N2    Zn1   Br1         133.79(6)     N4     Zn1          N2    133.47(8)
  N2    Zn1   Br2         108.28(6)     N4     Zn1          N3    95.22(7)
  N2    Zn1   N1          73.92(9)      N4     Zn1          N5    113.13(8)
  N2    Zn1   N3          79.37(9)      N5     Zn1          N1    96.56(7)
  N3    Zn1   Br1         99.01(6)      N5     Zn1          N2    113.35(8)
  N3    Zn1   Br2         102.71(5)     N5     Zn1          N3    98.97(8)
  C1    N1    Zn1         128.0(2)      C1     N1           Zn1   126.71(14)
  C5    N1    Zn1         113.25(18)    C5     N1           Zn1   114.26(14)
  C6    N2    Zn1         120.85(19)    C6     N2           Zn1   120.19(15)
  C8    N2    Zn1         115.86(19)    C8     N2           Zn1   114.51(17)
  C9    N3    Zn1         100.28(17)    C9     N3           Zn1   100.2(2)
  C13   N3    Zn1         115.48(17)    C10    N3           Zn1   112.0(2)
  C6    N2    C8          122.7(2)      C11    N3           Zn1   107.3(3)
  C8    N2    Zn1         115.86(19)    C9\'   N3           Zn1   104.0(2)
  C9    N3    C13         109.5(2)      C11    N3           Zn1   112.3(2)
  C1    N1    C5          118.7(3)      C12    N4           Zn1   162.3(2)
  C10   N3    C13         107.5(2)      C13    N5           Zn1   175.5(2)
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###### 

Crystal data for compounds **8** and **9**.

                                     8                                 9
  ---------------------------------- --------------------------------- -----------------------------------
  Empirical formula                  C~13~H~19~Br~2~N~3~OZn            C~13~H~17~N~5~S~2~Zn
  Formula weight                     458.50                            372.81
  Temperature/K                      100(2)                            100(2)
  Crystal system                     monoclinic                        monoclinic
  Space group                        P2~1~/n                           *P2~1~/n*
  a/Å                                9.8290(2)                         13.7663(2)
  b/Å                                14.0218(2)                        9.4949(2)
  c/Å                                12.1371(2)                        13.8089(2)
  β/°                                106.9180(10)                      109.9460(10)
  Volume/Å^3^                        1600.35(5)                        1696.68(5)
  Z                                  4                                 4
  ρ~calc~mg/mm^3^                    1.903                             1.459
  m/mm^−1^                           6.527                             1.693
  F(000)                             904                               768
  Crystal size/mm^3^                 0.33 × 0.25 × 0.11                0.35 × 0.31 × 0.19
  2Θ range for data collection       4.56 to 54°                       5.14 to 54°
  Reflections collected              12535                             15059
  Independent reflections            3496\[*R(int)* = 0.0351\]         3707\[*R(int)* = 0.0232\]
  Data/restraints/parameters         3496/0/182                        3707/14/225
  Goodness-of-fit on F^2^            1.028                             1.015
  Final R indexes \[I \>= 2σ (I)\]   *R~1~* = 0.0271, wR~2~ = 0.0595   *R~1~* = 0.0296, *wR~2~* = 0.0714
  Final R indexes \[all data\]       *R~1~* = 0.0360, wR~2~ = 0.0624   *R~1~* = 0.0402, *wR~2~* = 0.0772
  Largest diff. peak/hole/e Å^−3^    0.679/−0.466                      0.455/−0.428

Compound **9** is a square-pyramidal zinc(II) complex in which the metal center is coordinated by the *N,N′,N′′-*tridentate Schiff base and the *N* atoms of two thiocyanate ligands ([Figure 1](#molecules-17-05952-f001){ref-type="fig"}). The CH~2~*N*(CH~3~)~2~ fragment is disordered over two sets of sites in a 0.529 (4):0.471 (4) ratio. Like the structure of the zinc(II) thiocyanate complexes of similar Schiff bases \[[@B42-molecules-17-05952],[@B43-molecules-17-05952]\], the present structure is a mononuclear square-pyramidal metal complex, the τ value being 0.35. In contrast, the cadmium(II) thiocyanate complex of the same Schiff base \[[@B44-molecules-17-05952]\], showed a polymeric structure wherein the metal centers are linked by the N:S-bridging thiocyanate ligands. In the crystal structure of the title compound, C\-\--H\...S interactions connect a pair of molecules, related by symmetry −x+1, −y, −z, around a center of inversion. The zinc atom is bonded to three donor nitrogen atoms of the ligand and two thiocyanates both bonded through the nitrogen atoms. The five Zn-*N* bond lengths as apparent from ([Table 1](#molecules-17-05952-t001){ref-type="table"}) are given as Zn(1)-N(1) 2.1752(18) Å, Zn(1)-N(2) 2.0752(18) Å, Zn(1)-N(3) 2.217(2) Å, Zn(1)-N(4) 1.9681(18) Å, Zn(1)-N(5) 1.9698(19) Å.

2.5. Antibacterial Activity Results
-----------------------------------

A total of ten Schiff-bases compounds were synthesized and screened for potential antibacterial activity against the emerging multi-drug resistance nosocomial bacterial pathogens in hospital settings, namely, methicillin-resistant *Staphylococcus aureus*, *A. baumanii*, *K. pneumonia* and *P. aeroginosa*. In the first level antibacterial screening with the disc diffusion assay, all compounds under study were tested against eight clinical strains, two from each bacterial species. Inhibition zones were observed in the Schiff base compounds. However, no inhibition zone was observed in any of the compounds tested against *K. pneumonia* ([Table 3](#molecules-17-05952-t003){ref-type="table"}). All seven transition metal-bonded Schiff-base compounds were strongly inhibitive against MRSA, while they showed weak antibacterial activity against *A. baumanii* and *P. aeroginosa* in the disc diffusion test ([Table 3](#molecules-17-05952-t003){ref-type="table"}). This higher antimicrobial activity of the metal complexes **4**--**10**, compared with that of Schiff base ligands **1**--**3**, is perhaps due to the change in structure as a result of coordination, as chelating tends to make metal complexes act as more powerful and potent bacteriostatic agents, thus inhibiting the growth of the microorganisms \[[@B45-molecules-17-05952],[@B46-molecules-17-05952]\]. These seven compounds were then analyzed further for the MIC and MBC value using broth micro-dilution assay ([Table 4](#molecules-17-05952-t004){ref-type="table"}). The result from broth micro-dilution assay was in total analogue to the disk diffusion screening. The test showed that, all of the seven compounds were most active against MRSA, with MIC value ranged from 0.7--2.9 µg/mL; MBC value ranged from 2.9--46.9 µg/mL ([Table 4](#molecules-17-05952-t004){ref-type="table"}). Both *A. baumanii* and *P. aeroginosa* were resistant to the tested compounds at concentration lower than 93.8 and 187.0 µg/mL, respectively ([Table 4](#molecules-17-05952-t004){ref-type="table"}). Therefore, it was concluded that these seven compounds were highly inhibitive only against the Gram positive bacterium MRSA. Further antibacterial tests were conducted against eight clinical strains of multi-drug resistant MRSA ([Table 5](#molecules-17-05952-t005){ref-type="table"}) showing varying responses towards the seven selected Schiff-based compounds in the disc diffusion assay ([Figure 2](#molecules-17-05952-f002){ref-type="fig"}), however, they demonstrated twenty percent of resistance rate (two strains out of ten were resistant to the seven tested compounds). The broth micro-dilution assay resulted in similar findings, in which all, but MRSA 0807-1 and MRSA 0808-35, were inhibited at MIC ranging from "1.5 to 11.7" µg/mL. Both, MRSA 0807-1 and MRSA 0808-35, were only inhibited at MIC ranging from "209.7 to 419.4" µg/mL. ([Table 6](#molecules-17-05952-t006){ref-type="table"}) presented the antibiogram of ten clinical strains of MRSA used in this antibacterial analysis with some known antibacterial drugs in which MRSA either showed resistant (R), susceptible (S) or intermediate resistant (I) towards them.
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###### 

First level antibacterial screening Disc diffusion assay.

  Compound         MRSA 0804-25   MRSA 0807-7   AC 0612-7   AC 0903-21   KB 71   KB 83   PA 45   PA 104
  ---------------- -------------- ------------- ----------- ------------ ------- ------- ------- --------
  1                6              6             0           0            0       0       5       6
  2                5              5             0           0            0       0       5       5
  3                0              0             0           0            0       0       0       0
  4                21             22            7           7            0       0       8       8
  5                24             23            9           8            0       0       11      19
  6                22             23            9           8            0       0       10      10
  7                23             22            10          10           0       0       8       8
  8                21             20            10          9            0       0       9       9
  9                23             23            9           8            0       0       10      9
  10               22             22            7           7            0       0       10      9
  Control (DMSO)   0              0             0           0            0       0       0       0
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###### 

Second level antibacterial screening.

  Minimum inhibitory concentration (MIC; µg/mL)/minimum bactericidal concentration (MBC; µg/mL)                                                                                       
  ----------------------------------------------------------------------------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  1-3                                                                                             n.d.        n.d.        n.d.        n.d.        n.d.        n.d.        n.d.        n.d.
  4                                                                                               0.7/2.9     1.5/2.9     93.8/750    93.8/750    375/750     375/750     187.5/750   187.5/750
  5                                                                                               0.7/2.9     0.7/2.9     93.8/750    93.8/750    187.5/750   187.5/750   187.5/750   187.5/750
  6                                                                                               1.5/5.9     1.5/5.9     93.8/375    93.8/375    375/750     375/750     187.5/750   187.5/750
  7                                                                                               1.5/5.9     1.5/5.9     93.8/375    93.8/375    187.5/750   187.5/750   187.5/750   187.5/750
  8                                                                                               1.5/5.9     1.5/2.9     93.8/750    93.8/750    375/750     375/750     187.5/750   187.5/750
  9                                                                                               1.5/5.9     1.5/23.4    187.5/750   187.5/750   375/750     375/750     187.5/750   187.5/750
  10                                                                                              2.9/46.9    2.9/46.9    187.5/750   187.5/750   375/750     375/750     187.5/750   187.5/750
  DMSO                                                                                            375/\>375   375/\>375   375/\>375   375/\>375   375/\>375   375/\>375   375/\>375   375/\>375

n.d. = not determined.
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###### 

Varying responses of the eight MRSA clinical strains towards the seven selected Schiff-base complexes in the disc diffusion assay.

  Compounds    MRSA 0805-21   MRSA 0806-1   MRSA 0807-1   MRSA 0807-19   MRSA 0808-35   MRSA 0809-15   MRSA 0809-25   MRSA 0809-38
  ------------ -------------- ------------- ------------- -------------- -------------- -------------- -------------- --------------
  **4**        23             24            0             23             0              22             22             21
  **5**        23             24            0             25             0              23             23             23
  **6**        24             22            0             22             0              21             21             22
  **7**        24             20            0             21             0              19             20             20
  **8**        25             23            0             24             0              21             21             22
  **9**        23             23            0             22             0              23             24             23
  **10**       22             22            0             22             0              22             22             22
  **(DMSO)**   0              0             0             0              0              0              0              0

![Histogram for the 10 MRSA clinical strains of Schiff-base complexes.](molecules-17-05952-g002){#molecules-17-05952-f002}
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###### 

Antibiogram of the ten clinical strains of MRSA used in the antibacterial analysis.

  Strain No      E   CN   LZD   MUP   RD   DA   TEC   CIP   NET   TE   VA   FD   OX   SXT
  -------------- --- ---- ----- ----- ---- ---- ----- ----- ----- ---- ---- ---- ---- -----
  MRSA 0805-21   R   R    S     S     S    S    S     R     R     R    S    S    R    R
  MRSA 0806-1    R   R    S     S     S    S    S     R     R     R    S    S    R    R
  MRSA 0807-1    R   R    S     S     S    S    S     R     R     R    S    S    R    R
  MRSA 0807-19   R   R    S     S     S    S    S     R     I     S    S    S    R    S
  MRSA 0808-35   R   R    S     S     S    S    S     I     I     R    S    S    R    R
  MRSA 0809-15   R   R    S     S     S    S    S     R     R     R    S    S    R    R
  MRSA 0809-24   R   R    S     S     S    S    S     R     R     R    S    S    R    R
  MRSA 0809-38   R   R    S     S     S    S    S     R     R     R    S    S    R    S
  MRSA 0807-7    R   R    S     S     S    S    S     R     I     R    S    S    R    R
  MRSA 0804-25   R   R    S     S     S    S    S     R     S     S    S    S    R    S

E = erythromycin; GN = gentamycin; LZD-linozolid acid; MUP = muciprocin; RD- rifampicin; DA = clindamycin; TEC = teicoplanin; CIP = ciproflozaxin; NET = netilmycin; TE = tetracycline; VA = vancomycin; FD = fusicidic acid; OX = oxacilin; SXT = Trimethoprim-sulfamethaxazole; R = resistant; S = sensitive; I = intermediate resistant.

![Photograph showing the antibacterial (MRSA 0804-25-A,B,C) and (MRSA 0807-7-a,b,c) screening.](molecules-17-05952-g003){#molecules-17-05952-f003}

3. Experimental
===============

General
-------

Melting points were determined using a MEL-TEMP II melting point instrument and were not corrected. Microanalyses were carried out on a Perkin-Elmer 2400 elemental analyzer. ^1^H-NMR and ^13^C-NMR spectra were determined with a Lambda JEOL 400 MHz FT-NMR (^1^H: 400 MHz and ^13^C: 100.4 MHz) spectrometer. Chemical shifts are given in δ values (ppm) using TMS as the internal standard. The IR spectra were taken with a Perkin-Elmer RX1 FT-IR spectrophotometer.

*2-Morpholino-N-(1-(pyridin-2-yl)ethylidene)ethanamine*(**1**): A mixture of 4-(2-aminoethyl)-morpholine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 mmol) in ethanol (50 mL) was refluxed for 2 h followed by addition of few drops of glacial acetic acid. The obtained orange oil was solidified upon standing for 12 h at 55 °C in an oven.

The solid product was recrystallized in methanol. Yield: 61.5%. Molecular formula: C~13~H~19~N~3~O. Analysis Calculated: C, 66.92; H, 8.21; N, 18.01. Found: C, 67.02; H, 8.52; N, 17.99. IR (ATR cm^−1^) 2972.40 n(C-H), 1690.00, 1642.08 n(C=N), 1588.74, 1568.03 n(C=N)pyr, 1450.89 n(C-C), 1113.20 n(C-N), 1089.21 n(O-C). UV-Vis (DMSO), 281.00 (n→π\*); 224.00 (π→π\*). ^1^H-NMR (DMSO-*d~6~*), 8.69--7.95 (4H, CH-Ar), 3.79--3.837 (CH~2~-morph), 2.78--2.58 (NCH~2~-CH~2~N), 1.74 (CH~3~-). ^13^C-NMR (DMSO-*d~6~*). 164.53 \[1C, δ(C=N)\], 144.45 δ(C), 142.62 δ(CH), 136.40 δ(CH), 123.96 δ(CH), \[5C, δ(Ar-pyr)\], 61.23 \[2C, δ(2CH~2~)\], 52.08, 49.67 \[2C, δ(2CH~2~)\], 44.57 \[C, δ(CH~2~)\], 31.82 \[2C, δ(CH~2~)\], 14.52 \[C, δ(CH~3~)\].

*2-(Piperazin-1-yl)-N-(1-(pyridin-2-yl)ethylidene)ethanamine*(**2**): A mixture of 4-(2-aminoethyl)-piperazine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 mmol) in ethanol (50 mL) was refluxed for three hours followed by addition of few drops of glacial acetic acid.

The same procedure as for **1** was applied as the prototype in the isolation of other Schiff bases. Yield: 40.3%. Molecular formula: C~13~H~20~N~4~. Analysis Calculated: C, 67.21; H, 8.68; N, 24.12. Found: C, 68.19; H, 8.89; N, 24.48. IR (ATR cm^−1^) 3308.37 n(N-H), 2945.30 n(C-H), 1640.05 n(C=N), 1586.63 n(C=N)pyr, 1464.94, 1436.55 n(C-C), 1132.42 n(C-N). UV-Vis (DMSO) 281.00 (n→π\*); 224.00 (π→π\*). ^1^H-NMR (DMSO-*d~6~*) 8.30--7.85 (4H, CH-Ar), 3.98--3.69 (CH~2~-Pip.), 2.9 (NH-) 2.75--2.55 (NCH~2~-CH~2~N), 1.21 (CH~3~-). ^13^C-NMR (DMSO-*d~6~*) 168.43 \[1C, δ(C=N)\], 148.47 δ(C), 140.44 δ(CH), 127.93 δ(CH), 123.79 δ(CH), \[5C, δ(Ar-pyr)\], 51.72 \[2C, δ(2CH~2~)\], 44.19 \[2C, δ(2CH~2~)\], 42.04 \[2C, δ(CH~2~)\], 15.79 \[1C, δ(CH~3~)\].

*N1,N1-Dimethyl-N2-(1-(pyridin-2-yl)ethylidene)ethane-1,2-diamine*(**3**): An accurately measured amount of 2-acetylpyridine (0.61 g, 5 mmol) and *N*,*N*-dimethylethyldiamine (0.44 g, 5 mmol) in ethanol (25 mL) was refluxed for three hours.

Yield: 54%. Molecular formula: C~11~H~17~N~3~ (191.27). Analysis Calculated: C, 69.87; H, 8.80; N, 13.58. Found: C, 68.48; H, 8.98; N, 14.98. IR (ATR cm^−1^) 2925.46 n(C-H) 1639.70 n(C=N) 1566.34 n(C=N)pyr, 1464.83, 1435.25 n(C-C), 1153.71, 1103.38 n(C-N). UV-Vis (DMSO) 321 (n→π\*); 233 (π→π\*).^1^H-NMR (DMSO-*d~6~*) 8.28--7.87 (CH~2~-Ar), 2.76--2.68 (NCH~2~-CH~2~N), 1.22 (CH~3~-), 1.9 (6H, CH~3~-N). ^13^C-NMR (DMSO-*d~6~*) 166.59 \[1C, δ(C=N)\], 147.58 δ(C), 145.83 δ(CH), 139.56 δ(CH), 126.82 δ(CH), \[5C, δ(Ar-pyr)\], 54.43 \[2C, δ(2CH~2~)\], 43.44. 43.29 \[2C, δ(2CH~3~)\], 14.69 \[1C, δ(CH~3~)\].

*Aqua{Dithiocyanato-(2-morpholino-N-\[1-(2-pyridylethylidene\]ethanamine N,N\',N\'\'}cadmium(II)*(**4**): A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 g, 1.65 mmol) in ethanol (20 mL) was refluxed for 2 h followed by addition of a solution of cadmium(II) acetate dihydrate (0.44 g, 1.65 mmol) and sodium thiocyanate (0.268 g, 3.30 mmol) in a minimum amount of water. The mixture was refluxed for 2--3 h resulting in the formation of small amount of precipitate. More precipitate was obtained by removal of some solvent.

The product was collected by filtration, washed several times with ethanol until a white colored compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the suspended impurities. Yield = 75%. Melting point \>400 °C. Analysis Calculated: \[C, 39.09; H, 4.37; N, 18.23; S, 13.91\]. Found: \[C, 39.29; H, 4.17; N, 18.13; S, 13.61\]. IR (ATR cm^−1^) 2981.09 n(C-H), 2157.91, 2083, n(N=C=S), 1651.16 n(C=N), 1438.25 n(C-C), 1107.15 n(C-N), 659.88 n(OH~2~) 565.42 n(M-N). UV-Vis (DMSO) 407 (LMCT), 285 (n→π\*); 234 (π→π\*). ^1^H-NMR (DMSO-*d~6~*) 8.80 \[s, 1H, δ(Ar-H)pyr\], 8.29--8.24 \[m, 2H, δ(Ar-H)pyr\], 7.87--7.85 \[t, 1H, δ(Ar-H)pyr\], 3.80, 3.76 \[d, 4H, δ(2CH~2~)\], 3.69 \[s, 4H, δ(2CH~2~)\], 2.79--2.77 \[t, 4H, δ(N-CH2)\], 2.69 \[s, 3H, δ(CH~3~)\]. ^13^C-NMR (DMSO-*d~6~*) 165.80 \[1C, δ(C=N)\], 149.24 δ(C), 140.55 δ(CH), 132.31 δ(CH), 127.68 δ(CH), 124.29 δ(CH) \[5C, δ(Ar-pyr)\], 64.76, 57.88 \[4C, δ(2CH~2~) morph\], 53.44, 44.36 \[2C, δ(2CH~2~)\], 21.98 \[δ(SCN)\], 15.77 \[1C, δ(CH~3~)\].

*Aqua{Dichlorido Piperazin-4-ium1-(2-pyridyl)ethylidene\]ethanamine N,N′,N′′}cadmium*(**5**): A mixture of 2-acetylpyridine (0.61 g, 5 mmol) and 4-(2-aminoethyl)piperazine (0.65 g, 5 mmol) in ethanol (50 mL) was refluxed for 2 h followed by addition of a solution of cadmium(II) chloride (0.92 g, 5 mmol) in a minimum amount of water was added. The mixture was refluxed for 2--3 h resulting in the formation of white precipitate.

More precipitate was obtained by removal of some solvent. Analysis Calculated: C, 23.61; H, 3.55; N, 10.14. Found: C, 23.65; H, 3.75; N, 10.24. IR (ATR cm^−1^) 3469.07 n(N-H), 2953.13 n(C-H), 1654.02 n(C=N), 1438.11 n(C-C), 1121.21 n(C-N), 652.14 n(OH~2~) 557.10 n(M-N). UV-Vis (DMSO) 497 (LMCT), 281 (n→π\*); 229 (π→π\*). ^1^H-NMR (DMSO-*d~6~*) 8.73--7.83 \[m, 4H, δ(Ar-H)pyr\], 3.92, 3.81 \[d, 4H, δ(2CH~2~)\], 3.3--3.0 \[t, 4H, δ(2CH~2~)\], 2.82--2.80 \[2H, δ(N-CH2)\], 2.76 \[2H, δ(NH-)\], 2.38--2.36 \[t, 2H, δ(CH~2~=)\], 2.30 \[sbr, 1H, δ(NH)\] 2.23 \[s, 3H, δ(CH~3~)\]. ^13^C-NMR (DMSO-*d~6~*) 166.938 \[1C, δ(C=N)\], 157.942, 146.101, 137.967, 131.059, 124.085 \[5C, δ(Ar-pyr)\] 108.095, 106.975 \[δ(2CH~2~)\], 69.65 \[2C, δ(2CH~2~)\], 40.67 \[1C, δ(CH~2~)\], 46.00 \[1C, δ(CH~2~)\], 18.95 \[1C, δ(CH~3~)\].

*Chlorido(2-{1-\[(2-morpholinoethyl)imino\]ethyl}phenolato N,N′,N′′)copper(II)*(**6**): A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl) morpholine (0.21 g, 1.65 mmol) in ethanol (20 mL) was refluxed. After 2 h a solution of copper (II) chloride dihydrate (0.28 g, 1.65 mmol) in a minimum amount of ethanol was added. The mixture was refluxed for 2--3 h resulting in the formation of a small precipitate. More precipitate was obtained by removal of some solvent.

The product was collected by filtration, washed several times with ethanol until a green colored compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the suspended impurities. Yield = 77%. Melting point 375--380 °C. Analysis Calculated: \[C, 42.46; H, 5.21; N, 11.43\]. Found: \[C, 42.19; H, 5.11; N, 11.39\]. IR (ATR cm^−1^) 2949.37 n(C-H), 1654.51 n(C=N), 1443.03 n(C-C), 1144.39 n(C-N), 577.38 n(M-N). UV-Vis (DMSO) 645.50 (d→d\*); 337.00 (LMCT); 309.00 (n→π\*); 223.00, 219.00 (π→π\*).

*Dibromido{2-morpholino-N-\[1-(2-pyridyl ethylidene ethanamine N,N′,N′′}cadmium*(**7**): A mixture of 4-(2-aminoethyl)morpholine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 mmol) in ethanol (50 mL) was refluxed for 2 h followed by addition of a solution of cadmium(II) acetate dihydrate (0.44 g, 1.65 mmol) and potassium bromide (0.196 g, 1.65 mmol) in a minimum amount of water was added. The mixture was refluxed for 2--3 h resulting in the formation of a white precipitate. More precipitate was obtained by removal of some solvent.

The product was collected by filtration, washed several times with ethanol until a white colored compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the suspended impurities. Yield = 81%. Melting point \>400 °C. Analysis Calculated: C, 37.48; H, 4.60; N, 10.09. Found: C, 37.28; H, 4.45; N, 10.19. IR (ATR cm^−1^) 296202 n(C-H), 1650.04 n(C=N), 1458.80 n(C-C), 1115.11 n(C-N), 556.01 n(M-N). UV-Vis (DMSO) 398 (LMCT), 279 (n→π\*); 229 (π→π\*). ^1^H-NMR (DMSO-*d~6~*) 8.69--8.68 \[d, 1H, δ(Ar-H)pyr\], 8.29--8.24 \[m, 2H, δ(Ar-H)pyr\], 7.85 \[s, 1H, δ(Ar-H)pyr\], 3.93, 3.80 \[d, 4H, δ(2CH~2~)\], 3.73--3.71 \[t, 2H, δ(N-CH2)\], 2.81, 2.80, 2.80, 2.72, 2.70 \[m, 6H, δ(3CH~2~) morph\], 2.55 \[s, 3H, δ(CH~3~)\]. ^13^C-NMR (DMSO-*d~6~*) 166.90 \[1C, δ(C=N)\], 149.13 δ(C), 147.64 δ(CH), 140.55 δ(CH), 127.72 δ(CH), 124.42 δ(CH), \[5C, δ(Ar-pyr)\], 64.65 \[2C, δ(2CH~2~)\], 53.49 \[2C, δ(2CH~2~)\], 36.00 \[1C, δ(CH~2~)\], 30.67 \[1C, δ(CH~2~)\], 15.95 \[1C, δ(CH~3~)\].

*Dibromido {2-morpholino-N-\[1-(2-pyridyl) ethylidene\] ethanamine N,N′,N′′}zinc*(**8**): A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl) morpholine (0.21 g, 1.65 mmol) in ethanol (20 mL) was refluxed. After 2 h a solution of zinc (II) acetate dihydrate (0.36 g, 1.65 mmol) and potassium bromide (0.196 g, 1.65 mmol) in a minimum amount of water. The mixture was refluxed for 2--3 h resulting in the formation of a small amount of precipitate. More precipitate was obtained by removal of some solvent.

The product was collected by filtration, washed several times with ethanol until a milky colored compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the suspended impurities and a single crystal was obtained suitable for x-ray analysis. Yield = 85%. Melting point \>400 °C. Analysis Calculated: C, 30.89; H, 3.79; N, 8.31. Found: C, 30.79; H, 3.49; N, 8.28. IR (ATR cm^−1^) 2959.01 n(C-H), 1649.00 n(C=N), 1439.00 n(C-C), 1114.11 n(C-N), 561.12 n(M-N). UV-Vis (DMSO) 498 (LMCT), 289 (n→π\*); 229 (π→π\*). ^1^H-NMR (DMSO-*d~6~*) 8.78, 8.77 \[d, 1H, δ(Ar-H)pyr\], 8.30--8.25 \[m, 2H, δ(Ar-H)pyr\], 7.89--7.87 \[t, 1H, δ(Ar-H)pyr\], 3.89 \[s, 4H, δ(2CH~2~)\], 3.85--3.83 \[t, 2H, δ(CH~2~)\], 2.91--2.90 \[t, 6H, δ(N-CH2)\], 2.62 \[s, 3H, δ(CH~3~)\]. ^13^C-NMR (DMSO-*d~6~*) \[1C, δ(C=N)\], 168.38 δ(C), 146.49 δ(CH), 140.65 δ(CH), 128.03 δ(CH), 124.05 δ(CH) \[5C, δ(Ar-pyr)\], 62.88 \[2C, δ(2CH~2~)\], 54.55 \[2C, δ(2CH~2~)\], 52.09 \[1C, δ(CH~2~)\], 44.12 \[1C, δ(CH~2~)\], 15.86 \[1C, δ(CH~3~)\].

*N,N-Dimethyl-N\'-\[1-(2-pyridyl)ethylidene\]ethane-1,2-diamine-^3^N,N′,N′′}bis(thiocyanate)zinc(II)*(**9**): A mixture of 2-acetylpyridine (0.61 g, 5 mmol) and *N*,*N*-dimethylethyldiamine (0.44 g, 5 mmol) in ethanol (50 mL) was refluxed for 2 h followed by addition of a solution of Zinc (II) acetate (0.92 g, 5 mmol) and sodium thiocyanate (0.406 g, 5 mmol) in a minimum amount of water. The mixture was refluxed for 2--3 h resulting in the formation of a white precipitate. More precipitate was obtained by removal of some solvent.

The product was collected by filtration, washed several times with ethanol until a white colored compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the suspended impurities. Yield = 72%. Melting point 370--375 °C. Analysis Calculated: C, 35.27; H, 4.57; N, 11.22. Found: C, 35.17; H, 4.67; N, 11.21. IR (ATR cm^−1^) 2949.02 n(C-H), 2070.00 n(N=C=S), 1655.03 n(C=N), 1438.38 n(C-C), 1139.09 n(C-N), 477.06 n(M-N). UV-Vis \[λ~max~ (nm) (DMSO)\]. UV-Vis (DMSO) 497 (LMCT), 321 (n→π\*); 233 (π→π\*). ^1^H-NMR (DMSO-*d~6~*) 8.65, 8.64 \[d, 1H, δ(Ar-H)pyr\], 8.35--8.32 \[m, 2H, δ(Ar-H)pyr\], 7.95--7.94, 7.93 \[m, 1H, δ(Ar-H)pyr\], 3.79--3.77 \[t, 2H, δ(N-CH2)\], 2.77--2.75 \[t, 2H, δ(CH~2~=)\], 2.59 \[s, 3H, δ(CH~3~)\], 2.39 \[s, 6H, δ(2CH~3~)\]. ^13^C-NMR (DMSO-*d~6~*) 168.74 \[1C, δ(C=N)\], 147.99 δ(C), 147.16 δ(CH), 141.36 δ(CH), 135.03 δ(CH), 128.50 δ(CH) \[5C, δ(Ar-pyr)\], 56.35 \[2C, δ(2CH~3~)\], 44.55 \[1C, δ(N-CH~2~)\], 44.32 \[1C, δ(CH~2~=)\], 22.75 \[δ(SCN)\], 15.88 \[1C, δ(CH~3~)\].

*Aqua {2-morpholino-N-\[1-(2-pyridyl)ethylidene\] ethanamine N,N′,N′′}bis(thiocyanato) nickel(II)*(**10**): A mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine(0.21 g, 1.65 mmol) in ethanol (20 mL) was refluxed for 2 h followed by addition of a solution of nickel(II) acetate tetrahydrate (0.41 g, 1.65 mmol) and sodium thiocyanate (0.134 g, 1.65 mmol) in a minimum amount of water. The mixture was refluxed for 2--3 h resulting in the formation of a greenish colored precipitate. More precipitate was obtained by removal of some solvent.

The product was collected by filtration, washed several times with ethanol until a green colored compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the suspended impurities. Yield = 68%. Melting point 365--370 °C. Analytical Calculated: C, 42.27; H, 4.97; N, 16.43; S, 15.05. Found: C, 42.31; H, 4.98; N, 16.43; S, 15.09. IR (ATR cm^−1^) 2980.11 n(C-H), 2082.19 n(N=C=S), 1651.60 n(C=N), 1441.21 n(C-C), 1106.78 n(C-N), 659.16 n(OH~2~) 515.83 n(M-N), 461.51 n(M-O). UV-Vis (DMSO) 745.00 (d→d\*); 574.00 (LMCT); 279.00 (π→π\*).

3.1. X-Ray Structure Analyses
-----------------------------

A single crystal of the complexes suitable for X-ray diffraction were mounted on a glass fibre using perfluoropolyether oil and cooled rapidly to 100 K in a stream of cold N~2~. Diffraction data were measured using a Bruker APEX II CCD area-detector diffractometer (graphite monochromated Mo Ka radiation, λ = 0.71073 Å). The orientation matrix, unit cell refinement and data reduction were all handled by the APEX II software (SAINT integration, SADABS absorption correction \[[@B47-molecules-17-05952]\]. The structure was solved using direct methods and vectors in the program SHELXS-97 \[[@B48-molecules-17-05952]\] and was refined by the full matrix least-squares method on F2 with SHELXL-97 \[[@B48-molecules-17-05952]\]. All the nonhydrogen atoms were refined anisotropically and all the hydrogen atoms were placed at calculated positions and refined isotropically. Drawings of the molecules were produced with XSEED \[[@B49-molecules-17-05952]\].

4. Pharmacology
===============

4.1. Bacterial Strains
----------------------

The antibacterial activities of the investigated compounds were tested against a panel of multi-drug resistant nosocomial bacterial pathogens, consisted of ten (10) isolates of methicillin-resistant *Staphylococcus aureus (MRSA)--MRSA 0804-25*, *MRSA 0805-21*, *MRSA 0806-1*, *MRSA 0807-1*, *MRSA 0807-7*, *MRSA 0807-19*, *MRSA 0808-35*, *MRSA 0809-15*, *MRSA 0809-24*, *MRSA 0809-38*; two (2) isolates of *Acinetobacter baumannii(AC)--AC 0612-7*, *AC 0903-21*, two (2) isolates of *Klebsiella pneumonia (KB)--KB 71*, *KB 83*, and two (2) isolates of *Pseudomonas aeruginosa (PA)--P. aeruginosa*. All tested bacterial strains of *MRSA* were of clinical origin and have shown resistance to at least four antibiotics ([Table 6](#molecules-17-05952-t006){ref-type="table"}). For each bacterial species, six to ten strains were included in the antibacterial study to capture possible drug resistance variation within species. All bacterial strains used in this study were obtained from the bacteria culture collection of Biomedical Science Laboratory, Institute of Graduate Studies University of Malaya, Kuala Lumpur, Malaysia.

### 4.1.1. Antimicrobial Testing

The synthesized compounds were first screened for potential antibacterial activity by testing against two randomly selected strains from each bacterial species, using disc diffusion assay \[[@B50-molecules-17-05952]\]. Briefly, a loopful of an overnight bacterial culture of each strain was suspended in sterile 0.85% saline (BDH) to the concentration of approximately 10^8^ cfu/mL (equivalent to 0.5 Mc Farland units) before inoculated evenly on the entire surface of Mueller Hinton agar (Oxoid) with a sterile cotton swab. Sterilized paper discs (Thermo Fisher, 6 mm diameter), impregnated with 30 µg of respective synthetic Schiff compound, and was placed on the inoculated agar plate. DMSO disc was used as a negative control in the test. The diameter of inhibition zone around the impregnated paper disc was measured after 18 h of incubation at 37 °C. All tests were performed in duplicate. Synthetic Schiff base compounds, in which inhibition zone was observed in any one of the four species tested, were selected for MIC and MBC determination with broth micro-dilution assay. Only compounds with MIC and MBC value lesser than "10 µg/mL" is considered potentially active against the corresponded bacterial species; and further tested against the entire collection of the corresponded bacterial species with disc diffusion assay. This was to determine the variation in the susceptibility responses to the tested compound within the bacterial species tested. The two selected strains for each species in the initial screening were: MRSA 0804-25 and MRSA 0807-7 for MRSA ([Figure 3](#molecules-17-05952-f003){ref-type="fig"}); AC 0612-7 and AC 0903-21 for *A. baumannii*; KB 71 and KB 83 for *K. pneumonia*; and PA45 and PA104 for *P. aeruginosa*.

### 4.1.2. MIC Determination

Minimum inhibition concentrations (MICs) were determined with a 96-well broth micro-dilution assay. The inoculum was prepared by suspending an overnight culture in a sterile 0.85% saline (BDH) to approximate 10^8^ cfu/mL (equivalent to 0.5 McFarland units) and further diluted in cation adjusted Mueller Hinton broth (CMHB; BD) to the concentration of 10^6^ cfu/mL. Two-fold serial dilutions of the tested compound were prepared in CMHB across the 96-well microtiter plate with the highest concentration starting from 750 ppm (750 µL/mL) in duplicate rows. The prepared suspension of the bacteria was added to each well except the negative control wells of the microtitre plate in a 1:1 ratio with final bacteria concentration of approximately "5 × 10^5^" cfu/mL. The inoculated microtitre plates were incubated at 37 °C for 24 h. The MIC was determined as the lowest concentration of the test compound that exhibits no visible growth. A further confirmative test was done by adding 30 µL of MTT dye (Sigma) to each well. Wells with color changes within 30--60 min incubation at room temperature were scored as positive growth. The lowest concentration of the tested compound that exhibits no color changes (yellow) is determined as the MIC value.

### 4.1.3. MBC Determination

The MBC, minimal bactericidal concentration was tested by sub culturing 100 µL from each well of the incubated plate into Mueller Hinton Agar. The MBC was determined as the lowest concentration of the test compound that exhibits no viable microorganism growth on the Mueller Hinton Agar plate. The antimicrobial compound is regarded as bactericidal if the MBC is not more than four times the MIC.

5. Conclusions
==============

In conclusion, Schiff-based complexes were highly inhibitive only against the Gram positive bacterium MRSA, and as such could be potential antibacterial drugs to control MRSA nosocomial infections in hospital settings.

Supplementary Data
==================

CCDC 851793 and 851794 contain the supplementary crystallographic data for complex **8** and complex **9**. These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html>, or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or Email: <deposit@ccdc.cam.ac.uk>.
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